Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $42.57, but opened at $43.81. Halozyme Therapeutics shares last traded at $43.42, with a volume of 453,499 shares traded.
Wall Street Analyst Weigh In
HALO has been the topic of several recent analyst reports. The Goldman Sachs Group upped their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a "neutral" rating in a report on Monday, July 22nd. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and lifted their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Morgan Stanley upped their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. Benchmark restated a "buy" rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $61.11.
Read Our Latest Report on Halozyme Therapeutics
Halozyme Therapeutics Trading Up 5.3 %
The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The stock has a market cap of $5.70 billion, a price-to-earnings ratio of 14.84, a P/E/G ratio of 0.42 and a beta of 1.29. The company has a fifty day simple moving average of $55.42 and a 200-day simple moving average of $53.53.
Insider Activity at Halozyme Therapeutics
In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 70,000 shares of company stock worth $4,042,500. 2.70% of the stock is owned by corporate insiders.
Institutional Trading of Halozyme Therapeutics
Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its stake in Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock valued at $175,194,000 after buying an additional 30,901 shares during the period. Congress Asset Management Co. raised its holdings in shares of Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock worth $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock worth $112,715,000 after acquiring an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Finally, Epoch Investment Partners Inc. grew its stake in Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company's stock valued at $58,319,000 after purchasing an additional 270,579 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Articles
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
